Meldonium Siede Effects. Stroke - the second most killer of people in Russia

Stroke is the second most "killer" of people around the world. Today in Russia, among the causes of death is the second stroke after myocardial infarction, and on this indicator Russia ahead of European countries.

"Stroke is on the first place in mortality in modern Russia, ranking first among the reasons for the reduction of life expectancy. Statistics states: at a stroke 30-day mortality rate is more than 30% ", - such data is held in Moscow press conference," The creators Mildronate against rumors and speculation, "voiced MD, Professor, Head. the Department of outpatient therapy, Russian State Medical University Medical Faculty them. Pirogov Irina Ivanovna Chukaeva. Actualizing the problem, the professor pointed out that, according to statistics, of the patients who survived a stroke, 30% are unable to walk on their own, 30% require constant care, and only 20% of the survivors can return to work. In addition, stroke recurrence occurs in one in five over the next 5 years.

"The problem of stroke in Russia is very serious, and the search for medicinal aid techniques in the framework of the basic treatment of stroke seems urgent problem of neurology - confirmed MD, professor, Academy of Natural Sciences, Head. Department of Neurology, Russian State Medical University. Pirogov, honored doctor of the Russian Federation Anatoly Fedin. - Unfortunately, our country is "the leader" in terms of mortality from stroke. At the same time, it is worth noting that there have been positive changes made possible by the current country program for the fight against strokes "in the past five years. According to the doctor, in the five years of the program, there was also a positive statistic, indicating a decrease in morbidity and mortality.

Undoubtedly, an important point of the program, in general, designed to ensure that the equipment, the services of specialists and drug assistance became available to a larger number of patients are also high-quality, affordable and effective medicines. One - cytoprotective means Mildronate.

The studies revealed a positive result from the inclusion Mildronats drug (meldonium) in complex drug therapy in patients with stroke, which resulted in reducing neurological deficit, raising the level of motor and activities of daily living.

"Mildronats (meldonium) has cardioprotective and neuroprotective action - that is, to protect the heart and brain of the patient's head, - says AI Fedin, noting that in the instructions for use of the drug in the second place there are acute (stroke) and chronic disorders of cerebral circulation. - Why talk about the neuroprotective effect of the drug? The fact that in cerebrovascular disorders - both acute and chronic - the so-called developing ischemic cascade, the cascade is a chain of adverse reactions. And break these reactions or influence on them - and is one of the challenges facing physicians. And then the therapeutic value of the drug Mildronats very great - thanks to it is possible to protect the brain and other organs from the damaging effects of free radicals generated during the cascade. "

To date, in respect of the preparation Mildronats accumulated huge evidence base. He published more than 150 scientific papers - the results of clinical trials, including multicentre trials, and with a large sample of patients. These studies were conducted Mildronate in accordance with the standards of Good Clinical Practice, therefore, have a high degree of evidence.

The professor stressed that among the drugs for the basic therapy in patients with stroke draw attention medicines with multifactorial influence, the use of which allows you to not only have an impact on the various links in the pathogenesis, but also to reduce the pill burden. Such drugs include, in particular, Mildronate. Mildronate effectiveness has been proven in hundreds of studies - a "help" the drug included in the complex therapy, which includes other medicines. "For us - practitioners - very important is the fact that a drug that we prescribe to their patients, has an extensive evidence base. Mildronat well studied in different groups of patients with different diagnoses. " Examples AI Fedin mentions studies on patients with minor stroke, a study on the use of the drug in chronic ischemia studies in patients in the postoperative period, studies of patients with brain injuries, as well as various studies of older people, including a study on the impact of the application of mildronat falling health, activities of daily living and cognitive impairment iissledovaniya aimed at studying the efficacy of preparatau patients with acute ischemic stroke. The professor stressed that all studies have shown that Mildronat has a positive effect - in patients receiving preparatv addition to the basic treatment of ischemic stroke, a statistically significant reduction in neurological deficit. In addition, the drug has a positive effect on cognitive function (memory, attention, mental performance), provides neuroprotection and reducing action.